




Supplemental figure 1: Kaplan-Meier overall survival of neuroblastoma patients across all stages and risk groups (n = 185) based on miRNA abundance in serum.



Supplemental figure 2: Kaplan-Meier overall survival of high-risk neuroblastoma based on miRNA abundance in serum.



Supplemental figure 1: miRNA abundance (log₁₀ normalized values) in 8 murine serum samples (1046, 1048, 1053, 1057, 1060, 1063, 1067 and 1085), 6 days before engraftment, and 11 days and 25 days after engraftment.



Supplemental figure 4: Serum abundance of disease burden miRNA markers changes during treatment of stage 4 neuroblastoma patients. Hierarchical clustering based on the normalized abundance levels of the disease burden miRNA markers in 10 samples from cohort 1 that have the highest and lowest average abundance level of the 9 disease burden miRNA markers, and 10 serially collected samples from 5 stage 4 (metastatic) neuroblastoma patients. This analysis reveals two clusters: (1) a cluster in which patients with a high-metastatic load from cohort 1 cluster together with the diagnostic and non-responder follow-up samples of the serially collected serum samples, and (2) a cluster in which patients with a low-metastatic load from cohort 1 cluster together with the responder follow-up samples of the serially collected serum samples.